M. D. Anderson Cancer Center SPORE in Multiple Myeloma

M.D. 安德森癌症中心 SPORE 治疗多发性骨髓瘤

基本信息

批准号：
8326179
负责人：
ROBERT ZYGMUNT ORLOWSKI
金额：
$ 230万
依托单位：
UNIVERSITY OF TX MD ANDERSON CAN CTR
依托单位国家：
美国
项目类别：
财政年份：
2010
资助国家：
美国
起止时间：
2010-09-22 至 2015-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8326179
关键词：
Accounting Adoptive Immunotherapy Agonist Animal Model Antibodies Apoptotic Appointment Autologous BIK gene Basic Science Berry Bioinformatics Biological Models Biology Biometry Biostatistics Core Cancer Center Cancer Center Support Grant Cell Death Cell physiology Cells Cessation of life Chairperson Characteristics Chemosensitization Clinic Clinical Clinical Research Clinical Sciences Clinical Trials Clinical Trials Design Collaborations Communities Comprehensive Cancer Center Conceptions Core Facility Correlative Study Cyclin-Dependent Kinase Inhibitor Cytokine Receptors DNA analysis Data Databases Dendritic Cells Development Disease Doctor of Medicine Doctor of Philosophy Drug resistance Electron Microscopy Facility Flow Cytometry Fostering Gap Junctions Gene Expression Profiling Generations Goals Grant Growth Head Hematologic Neoplasms Hematopoietic Stem Cell Transplantation High Dose Chemotherapy Histopathology Facility Immune response Immunoglobulin Idiotypes Immunologics Immunotherapy In Vitro K-Series Research Career Programs Keyhole Limpet Hemocyanin Learning Lymphoma MCL1 protein Malignant Neoplasms Medicine Membrane Microdomains Molecular Monitor Monoclonal Antibodies Morbidity - disease rate Multiple Myeloma Outcome PMAIP1 gene Paraproteins Pathology Pathway interactions Patients Pennsylvania Pharmaceutical Preparations Phase Physiological Plasma Cells Play Preparation Principal Investigator Process Progress Reports Protein Array Protocols documentation Quality of life Refractory Refractory Disease Regimen Relapse Reporting Research Research Personnel Residual Neoplasm Resource Sharing Resources Role Sampling Sampling Studies Schedule Science Services Source Specialized Program of Research Excellence Structure System T cell therapy T-Lymphocyte Teleconferences Testing Therapeutic Therapeutic Agents Therapeutic Clinical Trial Tissues Toxic effect Training Translating Translational Research Translations Transplantation Type I Epithelial Receptor Cell United States Universities University of Texas M D Anderson Cancer Center Vaccination Vaccine Therapy Vaccines Virginia Work X-linked IAP Yang base bench to bedside cancer therapy career development cellular imaging chemosensitizing agent clinically relevant design experience improved in vivo in vivo Model inhibitor/antagonist innovation insight mTOR protein meetings mortality multicatalytic endopeptidase complex multidisciplinary mutant neoplastic cell next generation novel novel strategies novel therapeutics pre-clinical professor programs receptor reconstitution research and development research facility small molecule success ubiquitin-protein ligase

项目摘要

Multiple myeloma is a clonal plasma cell malignancy which, despite recent treatment advances, remains incurable in the vast majority of the over 59,000 patients in the United States afflicted with this disease. Therefore, The University of Texas M. D. Anderson Cancer Center, in collaboration with The University of Pennsylvania and the Virginia Commonwealth University, is proposing this Specialized Program of Research Excellence (SPORE) in Multiple Myeloma. The primary goal of this program will be to translate promising new strategies from the bench to the bedside to reduce the morbidity and mortality, and improve the quality of life of multiple myeloma patients. To do so, a multidisciplinary, collaborative group of experienced investigators will be pursuing four highly innovative Projects: Project 1 - Combination Activated T-Cell and Vaccine Therapy in Myeloma (Kwak/Giralt/June/Stadtmauer) Project 2 - Anti-(32-microglobulin Antibodies as Therapeutic Agents for Multiple Myeloma (Yi/Wang) Project 3-Targeting the HDM-2 E3 Ligase in Multiple Myeloma (Orlowski/Weber) Project 4 - Targeting Multiple Myeloma by Combining CDK Inhibitors and Bcl-2 Antagonists (Grant/Wang/Dai/Dent) To provide the specialized expertise needed to maximize the success of the Projects, they will be supported by five Core Facilities: Core A - Administrative Core Facility (Orlowski/Kwak) Core B - Myeloma Tissue Core Facility (Kornblau/Wang/Davis/Lin) Core C - Animal Models Core Facility (Yi/Yang) Core D - Clinical Trials Core Facility (Weber/Stadtmauer/McLaughlin) Core E - Biostatistics and Bioinformatics Core Facility (Berry/Baladandayuthapani/Almeida/ Ramakrishnan) Also, the SPORE will attract new investigators with additional novel ideas, and train the next generation of myeloma researchers, through the following Programs: Developmental Research Program (OrlowskiA'i) Career Development Program (Kwak/Aggarwal/Stadtmauer) This SPORE will therefore serve as a nexus for its Investigators and the myeloma research community to foster the kind of multidisciplinary efforts that are necessary to bring us closer to a cure for this disease.

多发性骨髓瘤是一种克隆血浆细胞恶性肿瘤，尽管最近的治疗进展，但在美国59,000多名患者中，绝大多数患有这种疾病。因此，德克萨斯大学M. D. Anderson癌症中心与宾夕法尼亚大学和弗吉尼亚联邦大学合作，提议在多发性骨髓瘤中提出这项专业的研究卓越研究计划（SPORE）。该计划的主要目标是将有希望的新策略从长凳转换为床边，以降低发病率和死亡率，并改善多发性骨髓瘤患者的生活质量。为此，一个多学科的，合作的经验研究人员将追求四个高度创新的项目：项目1-骨髓瘤中激活的T细胞和疫苗疗法（Kwak/Giralt/June/Stadtmauer）项目2-多发性骨髓瘤（Yi/Wang）的治疗剂的抗（32-微球蛋白抗体（32-微球蛋白抗体）项目3靶向多发性骨髓瘤（Orlowski/Weber）中的HDM-2 E3连接酶项目4-通过组合CDK抑制剂和Bcl -2拮抗剂（授予/王/dai/dent）来靶向多发性骨髓瘤为了提供最大化项目成功所需的专业专业知识，它们将得到五个核心设施的支持：核心A-行政核心设施（Orlowski/Kwak） Core B-骨髓瘤组织核心设施（Kornblau/Wang/Davis/Lin）核心C-动物模型核心设施（yi/yang）核心D-临床试验核心设施（Weber/Stadtmauer/McLaughlin）核心E-生物统计学和生物信息学核心设施（Berry/Baladandayuthapani/Almeida/Ramakrishnan）此外，孢子将通过以下程序吸引新的调查员，并通过以下程序来培训下一代骨髓瘤研究人员：发展研究计划（Orlowskia'i）职业发展计划（Kwak/Aggarwal/Stadtmauer）因此，该孢子将成为其研究人员和骨髓瘤研究界的联系，以促进那种多学科的努力，这些工作是使我们更接近这种疾病的治疗方法。